Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Haematologica|July 16, 2026
Teclistamab in relapsed/refractory Waldenstro m macroglobulinemiaMichal Kascak, Ludmila Muronova, Ondrej Venglar, et al.
British Journal of Haematology|October 9, 2023
Insight into the mechanism of CD34<sup>+</sup> cell mobilisation impairment in multiple myeloma patients treated with anti-CD38 therapyOndrej Venglar, Veronika Kapustova, Anjana Anilkumar Sithara, et al.
European Journal of Haematology|October 11, 2024
Real-World Evidence on Prognostic Value of MRD in Multiple Myeloma Using Flow CytometryLudmila Muronova, Ondrej Soucek, David Zihala, et al.
The Lancet. Haematology|July 18, 2025
Patient-reported outcomes with belantamab mafodotin, bortezomib, and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): results from a phase 3, open-label, randomised controlled trialVania Hungria, Marek Hus, ChengCheng Fu, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 3, 2025
Treatment Patterns and Outcomes in Over 2200 Newly Diagnosed Multiple Myeloma Patients: Supporting Bortezomib-Lenalidomide-Dexamethasone as a Preferred Regimen in the Absence of Anti-CD38 AntibodiesAlexandra Jungova, Martin Stork, Ivan Spicka, et al.
Hemasphere|September 25, 2025
Elevated circulating tumor cells reflect high proliferation and genomic complexity in multiple myelomaJuan-Jose Garces, Benjamin Diamond, Tereza Sevcikova, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 31, 2022
More Than 2% of Circulating Tumor Plasma Cells Defines Plasma Cell Leukemia-Like Multiple MyelomaTomas Jelinek, Renata Bezdekova, David Zihala, et al.
Blood Cancer Discovery|November 14, 2025
Composition and functional state of T and NK cells in the extramedullary myeloma tumor microenvironmentAnjana Anilkumar Sithara, Veronika Kapustova, David Zihala, et al.
Blood|December 17, 2025
Selective depletion of B-cell subsets underlies increased risk of infection in MM patients treated with anti-BCMA vs -GPRC5D bsAbsTomas Jelinek, David Žihala, Aintzane Zabaleta, et al.
Pageof 1